News stories about Ocata Therapeutics (NASDAQ:OCAT) have trended positive on Friday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ocata Therapeutics earned a media sentiment score of 0.35 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.6475045982409 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2802826/ocata-therapeutics-nasdaqocat-earns-daily-news-sentiment-score-of-0-35.html.
About Ocata Therapeutics
Ocata Therapeutics, Inc, formerly Advanced Cell Technology, Inc, is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration.
Receive News & Ratings for Ocata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.